目的 探讨茵栀黄注射液联合熊去氧胆酸治疗自身免疫性肝炎的临床疗效。方法 选取2015年5月-2016年5月在天津市第五中心医院接受治疗的自身免疫性肝炎患者84例，根据治疗方案的差别分为对照组（42例）和治疗组（42例）。对照组患者口服熊去氧胆酸胶囊，250 mg/次，3次/d。治疗组在对照组的基础上静脉滴注茵栀黄注射液，10 mL加入10%葡萄糖溶液250 mL，2次/d。两组患者均连续治疗8周。评价两组患者临床疗效，同时比较两组丙氨酸转氨酶（ALT）、天氨酸转氨酶（AST）、直接胆红素（DBIL）和总胆红素（TBIL）等肝功能，以及透明质酸（HA）、层黏蛋白（LN）、Ⅲ型前胶原（PC-Ⅲ）和Ⅳ型胶原（Ⅳ-C）等肝纤维化指标和血清IgG、IgM水平变化。结果 治疗后，两组患者总有效率分别为76.19%、92.86%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组ALT、AST、DBIL和TBIL水平均显著降低，同组治疗前后差异具有统计学意义（P<0.05），且治疗后治疗组肝功能水平优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清HA、LN、PC-Ⅲ和Ⅳ-C均明显降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组肝纤维化指标比对照组降低的更明显（P<0.05）。治疗后，两组患者血清IgG、IgM水平均明显降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组免疫学指标降低程度更显著，两组比较差异具有统计学意义（P<0.05）。结论 茵栀黄注射液联合熊去氧胆酸治疗自身免疫性肝炎具有很好的临床效果，能够促进肝功能改善，还可改善肝纤维化，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Yinzhihuang Injection combined with ursodeoxycholic acid in treatment of autoimmune hepatitis. Methods Patients (84 cases) with autoimmune hepatitis in the Fifth Center Hospital of Tianjin from May 2015 to May 2016 were divided into the control (42 cases) and treatment (42 cases) groups according to different treatments. The patients in the control group were po administered with Ursodeoxycholic Acid Capsules, 250 mg/time, three times daily. The patients in the treatment group were iv administered with Yinzhihuang Injection on the basis of the control group, 10 mL added into 10% glucose solution 250 mL, twice daily. The patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the changes of liver functions including ALT, AST, DBIL, and TBIL, and liver fibrosis indexes including HA, LN, PC-Ⅲ, and Ⅳ-C, also serum IgG and IgM levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there were differences between two groups (P<0.05). After treatment, the ALT, AST, DBIL, and TBIL levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the liver functions in the treatment group were significant better than those in the control group, with significant difference between two groups (P<0.05). After treatment, serum HA, LN, PC-Ⅲ, and Ⅳ-C levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the liver fibrosis indexes in the treatment group were significant lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, serum IgG and IgM levels were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decrease degree of the two indexes in the treatment group was more significant than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yinzhihuang Injection combined with ursodeoxycholic acid has a significant clinical effect in treatment of autoimmune hepatitis, can significantly improve the liver function and hepatic fibrosis, which has a certain clinical application value.